Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Press release

BioStock: Spago Nanomedical's promising cancer therapy approved for phase I/IIa

Spago Nanomedical

Spago Nanomedical has achieved a significant milestone in its cancer therapy development journey. The company's drug candidate, 177Lu-SN201, has received approval to initiate the clinical phase I/IIa study, Tumorad-01, in Australia. To fully appreciate this endeavour, BioStock reached out to Spago's CEO Mats Hansen.

Read the interview with Mats Hansen at biostock.se:

Spago Nanomedical's promising cancer therapy approved for phase I/IIa - BioStock (https://www.biostock.se/2023/10/spago-nanomedicals-promising-cancer-therapy-approved-for-phase-i-iia/)
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.